PatenSee Overview
PatenSee is a clinical-stage medical device company that has developed a contactless surveillance system designed to detect early asymptomatic vascular stenosis in hemodialysis patients. By harnessing advanced multimodal imaging technologies and machine learning, PatenSee aims to flag stenosis risk at the earliest stage, enabling care teams to perform simple interventions to protect the patient’s hemodialysis lifeline, improve quality of care, and prolong life expectancy.
Cumulative Funding Raised Over Time ($)
$1.6MFeb 2025
$2.4MMar 2019
Latest News
growth-positive
/PRNewswire/ -- PatenSee, a clinical-stage medical device company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
PatenSee, a clinical-stage medical device company, has received Breakthrough Device Designation from the FDA for its AI-driven vascular access management technology for hemodialysis patients. This designation will accelerate the development and adoption of PatenSees platform, which aims to improve patient outcomes and reduce clinical burdens. The company is currently conducting a clinical trial in collaboration with Henry Ford Health to validate its system. Additionally, PatenSee announced a $2 million seed round led by Michigan Rise, with participation from several other investors. The companys technology is designed to enable early detection of vascular access complications, potentially transforming dialysis care.
Product StageInvestmentFDA approved/pending approvalPartners
PatenSee, Fresenius Medical Care sign clinical collaboration agreement
growth-positive
חברת PatenSee מודיעה על תוצאות ניסוי קליני מוצלח במרכז הרפואי רבין
PatenSee, a medical technology company, presented successful interim results from a clinical trial at the World Neurology Conference in Malaysia. The trial, conducted at Rabin Medical Center, demonstrated the effectiveness of PatenSees non-invasive imaging device in early detection of blood vessel blockages in dialysis patients. The device allows for quick and simple testing of the vital lifeline artery without physical contact. The technology has the potential to improve treatment quality and prevent complications. The presentation was delivered by Prof. Binyah Rozin-Tzvi, the lead researcher of the clinical trial.
Customers
growth-positive
PatenSee's Contactless Imaging Device Shows Promise in Timely and Accurately Monitoring Dialysis Patients
PatenSee, a medical device company, shared the interim results of a clinical study on their contactless imaging device for the early detection of vascular access stenosis in dialysis patients. The studys principal investigator presented the results at a nephrology meeting. The device aims to provide quick and high-quality monitoring without physical contact, reducing the risk of infection. The results showed good correlation with a doppler ultrasound, suggesting the devices potential as an effective tool for automated surveillance. PatenSee is a portfolio company of MEDX Xelerator and is currently raising a series A funding for the next stages of its clinical program.
Customers
growth-positive
PatenSee's imaging device spots health abnormalities with the touch of a button
Israeli medical device startup PatenSee has developed a technology to treat kidney patients receiving dialysis treatments. The companys device helps vascular stenosis in hemodialysis patients by detecting risks and predicting problems ahead of time. The device conducts simple optical imaging and takes a photo of the arm to discover patterns related to the early development of stenosis issues. PatenSee aims to obtain FDA and CE approval and is waiting for the full results from clinical trials before commercializing its technology. The company has raised a seed round of NIS 2.5 million ($750,000) from various investors, including the Israel Innovation Authority, MedX Xelerator, MEDX Ventures, Boston Scientific, and Intellectual Ventures.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.35M |
| Last funding | $1.6M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 4 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | patensee.com |
Locations
Ariel Sharon Boulevard 8, Or Yehuda, Israel
Photos & Videos
1 item(s)
PatenSee Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesDigital HealthcareTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Artificial IntelligenceMachine LearningPlatforms & InterfacesSoftwareSimulation & ImagingTags (12)
early-detectionmedical-technologiesvascularremote-monitoringimagingdigital-healthcaredialysismedical-devicesmachine-learningartificial-intelligencehospitalsnon-invasivePatenSee Financials
$2.35M
Total funding
Undisclosed
Capital raised
$1.6M
Last funding
Seed
Funding stage
2
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$1.6MFeb 2025
$2.4MMar 2019
Private Equity Funding
Undisclosed Round
Feb 2025
$1.6M
Seed
Mar 2019
$750K
Israel Innovation Authority, MEDX Ventures Group, Intellectual Ventures, MEDX Xelerator
PatenSee Lifecycle
Cumulative Funding Raised Over Time
$1.6MFeb 2025
$2.4MMar 2019
All Events
Undisclosed Round
Feb 2025
$1.6M
Seed
Mar 2019
$750K
Israel Innovation Authority, MEDX Ventures Group, Intellectual Ventures, MEDX Xelerator
PatenSee News
6 articles
growth-positive
/PRNewswire/ -- PatenSee, a clinical-stage medical device company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
PatenSee, a clinical-stage medical device company, has received Breakthrough Device Designation from the FDA for its AI-driven vascular access management technology for hemodialysis patients. This designation will accelerate the development and adoption of PatenSees platform, which aims to improve patient outcomes and reduce clinical burdens. The company is currently conducting a clinical trial in collaboration with Henry Ford Health to validate its system. Additionally, PatenSee announced a $2 million seed round led by Michigan Rise, with participation from several other investors. The companys technology is designed to enable early detection of vascular access complications, potentially transforming dialysis care.
Product StageInvestmentFDA approved/pending approvalPartners
PatenSee, Fresenius Medical Care sign clinical collaboration agreement
growth-positive
חברת PatenSee מודיעה על תוצאות ניסוי קליני מוצלח במרכז הרפואי רבין
PatenSee, a medical technology company, presented successful interim results from a clinical trial at the World Neurology Conference in Malaysia. The trial, conducted at Rabin Medical Center, demonstrated the effectiveness of PatenSees non-invasive imaging device in early detection of blood vessel blockages in dialysis patients. The device allows for quick and simple testing of the vital lifeline artery without physical contact. The technology has the potential to improve treatment quality and prevent complications. The presentation was delivered by Prof. Binyah Rozin-Tzvi, the lead researcher of the clinical trial.
Customers
growth-positive
PatenSee's Contactless Imaging Device Shows Promise in Timely and Accurately Monitoring Dialysis Patients
PatenSee, a medical device company, shared the interim results of a clinical study on their contactless imaging device for the early detection of vascular access stenosis in dialysis patients. The studys principal investigator presented the results at a nephrology meeting. The device aims to provide quick and high-quality monitoring without physical contact, reducing the risk of infection. The results showed good correlation with a doppler ultrasound, suggesting the devices potential as an effective tool for automated surveillance. PatenSee is a portfolio company of MEDX Xelerator and is currently raising a series A funding for the next stages of its clinical program.
Customers
growth-positive
PatenSee's imaging device spots health abnormalities with the touch of a button
Israeli medical device startup PatenSee has developed a technology to treat kidney patients receiving dialysis treatments. The companys device helps vascular stenosis in hemodialysis patients by detecting risks and predicting problems ahead of time. The device conducts simple optical imaging and takes a photo of the arm to discover patterns related to the early development of stenosis issues. PatenSee aims to obtain FDA and CE approval and is waiting for the full results from clinical trials before commercializing its technology. The company has raised a seed round of NIS 2.5 million ($750,000) from various investors, including the Israel Innovation Authority, MedX Xelerator, MEDX Ventures, Boston Scientific, and Intellectual Ventures.
InvestmentExpand
PatenSee Initiates First In-Human Trial with its Contactless Imaging Surveillance System for Patients Undergoing Hemodialysis
PatenSee Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 16 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
PatenSee Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516013224 |
| Phone | +972722513566 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-22T00:00:00.000Z |
| Created | 2019-03-21T00:00:00.000Z |